RATIO-METFORMIN 500 MG
METFORMIN HYDROCHLORIDE : 500 MG · DIN 02242974 · TEVA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is RATIO-METFORMIN?
RATIO-METFORMIN 500 MG contains METFORMIN HYDROCHLORIDE : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02242974, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 30-Jul-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RATIO-METFORMIN used for?
Adjunct to diet and exercise to improve glycemic control in adult patients with responsive, stable, mild, non-ketosis prone, type 2 diabetes mellitus. Monotherapy or combination therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02242974 |
|---|---|
| Brand name | RATIO-METFORMIN |
| Generic / active ingredient | METFORMIN HYDROCHLORIDE : 500 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 500 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BA02 METFORMIN |
| AHFS class | 68:20.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 30-Jul-2021 |
| Original market date | 2001-01-04 00:00:00 |
How is it administered?
Administer orally. Dosage must be individualized. Use minimum effective dose. Titrate carefully in elderly. Discontinue 2 days before surgery or iodinated contrast studies.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section header present but content truncated).
How is it supplied?
Not explicitly detailed in provided text (mentions 500 mg and 850 mg tablets).
Contraindications
Type 1 diabetes; metabolic acidosis; history of lactic acidosis; renal impairment (CrCl <60 mL/min); excessive alcohol; severe hepatic dysfunction; pregnancy/breastfeeding; severe dehydration.
Warnings and precautions
Serious Warning: Lactic acidosis is a rare, fatal metabolic complication. Avoid excessive alcohol. Risk increases with renal impairment and age. Monitor Vitamin B12 and TSH levels.
What can be used instead?
Other Canadian products sharing ATC code A10BA02 METFORMIN. 45 of 122 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-METFORMIN | 500 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02494418 |
| AG-METFORMIN | 850 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02494442 |
| APO-METFORMIN ER | 1000 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02460653 |
| APO-METFORMIN ER | 500 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02305062 |
| AURO-METFORMIN | 850 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02438283 |
| GLUCOPHAGE | 500 MG | TABLET | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02099233 |
| GLUMETZA | 1000 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02300451 |
| GLUMETZA | 500 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02268493 |
| JAMP METFORMIN | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02380196 |
| JAMP METFORMIN | 850 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02380218 |
Who else supplies METFORMIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METFORMIN appears in 1377 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.